Maithili Life Sciences Celebrates Success at CPHI Korea 2024: Leading the Way in High-Quality APIs for South Korea
Maithili Life Sciences is proud to announce the successful conclusion of our participation in the CPHI Korea event, held in Seoul from August 27th to 29th, 2024. This significant event provided an excellent platform to showcase our comprehensive range of high-quality Active Pharmaceutical Ingredients (APIs) and intermediates, reinforcing our position as a leading API supplier in South Korea and the broader Asian market.
Strengthening Our Presence in South Korea
Our participation in CPHI Korea 2024 highlights our commitment to expanding our footprint in the South Korean pharmaceutical market. We engaged with key industry stakeholders, discussing innovative solutions and forming strategic partnerships to better serve the local market’s needs.
Why Maithili Life Sciences is the Preferred API Supplier
- High-Quality APIs: Our state-of-the-art manufacturing facilities and stringent quality control processes ensure that we provide top-quality APIs that meet global standards.
- Extensive Product Range: We offer a diverse portfolio of APIs and intermediates covering various therapeutic areas, including cardiovascular, CNS, anti-infective, oncology, and more.
- Regulatory Compliance: We comply with international regulatory standards such as USFDA, EU-GMP, and WHO-GMP, as well as local requirements set by South Korea’s Ministry of Food and Drug Safety (MFDS).
- Innovative R&D: Our dedicated R&D team continuously works on developing new and improved APIs, ensuring that we stay ahead in a competitive market.
Extensive Product Portfolio
Our comprehensive range of APIs and intermediates includes products across various therapeutic categories, such as:
- Azilsartan Medoxomil Potassium Salt: An angiotensin II receptor antagonist used to treat high blood pressure.
- Benazepril HCl: An ACE inhibitor for treating hypertension.
- Irbesartan: Used to treat high blood pressure and diabetic nephropathy.
- Nebivolol HCl: A beta-blocker that treats high blood pressure.
- Telmisartan: An angiotensin receptor blocker (ARB) for managing hypertension.
- Brivaracetam: Used as an anticonvulsant for epilepsy.
- Modafinil: Promotes wakefulness in conditions like narcolepsy.
- Rasagiline Mesylate: Used in the treatment of Parkinson’s disease.
- Trazodone: An antidepressant used for major depressive disorder.
- Ornidazole: An antibiotic used to treat infections caused by anaerobic bacteria and protozoa.
- Favipiravir: An antiviral used to treat influenza and COVID-19.
- Voriconazole: An antifungal medication for serious fungal infections.
- Etoricoxib: A COX-2 inhibitor for osteoarthritis and rheumatoid arthritis.
- Zaltoprofen: A non-steroidal anti-inflammatory drug (NSAID).
- Cabergoline Intermediates: Used in the treatment of hyperprolactinemia and pituitary tumors.
- Dabigatran Etexilate Mesylate: An anticoagulant used to prevent strokes and blood clots.
- Darolutamide Intermediates: Used in the treatment of non-metastatic castration-resistant prostate cancer.
- Minoxidil: Primarily used for its ability to promote hair growth.
- Dapoxetine HCl: Used for treating premature ejaculation.
- Solifenacin Succinate: Used to treat overactive bladder.
- Sumatriptan Succinate: For the treatment of migraine headaches.
- Tadalafil: Used to treat erectile dysfunction and benign prostatic hyperplasia.
- Tamsulosin: Treats benign prostatic hyperplasia.
- Ticagrelor: An antiplatelet medication to reduce cardiovascular events.
- Torsemide: A diuretic for treating edema and hypertension.
- Sildenafil: Treats erectile dysfunction and pulmonary arterial hypertension.
- Vardenafil: Used to treat erectile dysfunction.
Building a Sustainable Future
Through events like CPHI Korea 2024, Maithili Life Sciences continues to demonstrate our commitment to innovation, quality, and customer satisfaction.
We aim to build a sustainable future by developing reliable, high-quality pharmaceutical solutions that address the evolving needs of the South Korean market.
Get in Touch
For more information about Maithili Life Sciences and our extensive range of APIs and intermediates, please contact us at [email protected] or visit our website www.maithililifesciences.com.
Thank you for visiting us at CPHI Korea 2024. We look forward to building strong partnerships and driving the future of healthcare together.
